Carlos Aguilar, PA
Medical · Tucson, AZNPI 1477520484
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 96 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 19 manufacturers, the largest accounting for just 18.7% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $3,138, 2.3 times the $1,352 reported in 2021. Among medical clinicians in AZ with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 96 payments — averaging $84.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$2K
- AstraZeneca$2K
- Abbott$1K
- GSK$704
- AbbVie$571
- Amgen$515
- plus $2K from 13 others
What the payments were for
- Food & beverage$8,148100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 29 | $1,520 |
| AstraZeneca | 21 | $1,517 |
| Abbott | 10 | $1,062 |
| GSK | 6 | $704 |
| AbbVie | 5 | $571 |
| Amgen | 4 | $515 |
| Bayer | 4 | $370 |
| Lilly USA, LLC | 3 | $304 |
| Boehringer Ingelheim | 2 | $232 |
| Johnson & Johnson | 2 | $215 |
| Medtronic | 1 | $203 |
| Sanofi-aventis U.S. LLC | 2 | $179 |
| Bard Peripheral Vascular, Inc. | 1 | $136 |
| Stryker | 1 | $130 |
| Mylan Specialty L.p. | 1 | $125 |
| Nestle Healthcare Nutrition Inc. | 1 | $110 |
| Aimmune Therapeutics, Inc. | 1 | $105 |
| Averitas Pharma Inc. | 1 | $94 |
| Teleflex LLC | 1 | $56 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Ozempic$518
- FREESTYLE LIBRE 3$505
- RYBELSUS$501
- Repatha$390
- FARXIGA$384
- FreeStyle Libre 2$380
- TEZSPIRE$375
- Kerendia$365
- Wegovy$362
- VRAYLAR$250
- BREZTRI$246
- AREXVY$244
- SHINGRIX$240
- JARDIANCE$232
- ZENPEP$215
- INTERSTIM$203
- XARELTO$139
- VENOVO$136
- FLOWTRIEVER CATHETER, S$130
- CT THROMBECTOMY SYSTEM KIT$130
How this compares
$8,148 in reported general payments places this provider in the 90th percentile of 748 medical providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 120 | $197,248 |
| TrulicityDulaglutide | 92 | $179,993 |
| FarxigaDapagliflozin Propanediol | 108 | $146,035 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 72 | $102,021 |
| JardianceEmpagliflozin | 59 | $87,686 |
| VascepaIcosapent Ethyl | 83 | $84,835 |
| AustedoDeutetrabenazine | 12 | $58,331 |
| LinzessLinaclotide | 34 | $51,210 |
| RybelsusSemaglutide | 17 | $46,862 |
| ProliaDenosumab | 24 | $42,749 |
| EliquisApixaban | 25 | $34,940 |
| XareltoRivaroxaban | 20 | $33,159 |
| Breo ElliptaFluticasone/Vilanterol | 47 | $29,405 |
| InvokanaCanagliflozin | 18 | $23,377 |
| MounjaroTirzepatide | 15 | $20,435 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $1,520 | $244,110137 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $304 | $200,427107 claims |
| AstraZenecaFarxiga, Symbicort | $1,517 | $152,773130 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33, Lantus | $179 | $107,685111 claims |
| Boehringer IngelheimJardiance | $232 | $87,68659 claims |
| Johnson & JohnsonXarelto, Invokana | $215 | $56,53638 claims |
| GSKBreo Ellipta, Anoro Ellipta, Trelegy Ellipta | $704 | $56,46678 claims |
| AbbVieLinzess | $571 | $51,21034 claims |
| AmgenProlia | $515 | $42,74924 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 748 medical providers in Arizona.
Other medical in Tucson
- Linda MoorsTucson$122K
- Danielle WergeTucson$27K
- Darek AndersonTucson$10K
- Robert CasquejoScottsdale$474K
- Andrew HicksPeoria$460K
- Darren WestScottsdale$206K
- Jamie WystrachScottsdale$79K
- Scott YoungPhoenix$69K
- Scott LightfootPhoenix$61K
- Jennifer KiserPhoenix$53K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.